GUILLAIN-BARRẺ SENDROMU 

Tanım: ―Akut inflamatuar Demyelinizan Polinöropati‖ (AIDP) olarak da bilinir. Motor ve duysal periferik sinirleri etkileyen, akut, progresif, paralizi yapan bir hastalıktır. 

Gerekçe: AIDP için muhtemel etyoloji, periferik sinir myelininde otoimmün, antikor aracılı hasar oluşmasıdır. Terapötik plazmaferez, motor düzelmeyi hızlandırır. Ventilatörde geçen zamanı kısaltır. 

İşlem: TPD / DFPP / CF / IA 

İşlenen Volüm: 1-1.5 TPH 

Sıklığı: Günaşırı 

Replasman Sıvısı: Albümin, HES 

Uygulama sayı ve/veya süresi: 10-14 gün boyunca genellikle 5 ila 6 işlem gerekmektedir. 

YARARLANILAN LİTERATÜRLER

The Guillain-Barre syndrome Study Group. Plasmapheresis and acute Guillain-Barre syndrome. Neurology 1985;35:1096–1104.

NIH Consensus Development. The utility of therapeutic plasmapheresis for neurological disorders. Jama 1986;256:1333– 1337. 

French Cooperative Group on Plasma Exchange in Guillain- Barre syndrome. Efficiency of plasma exchange in Guillain- Barre syndrome: role of replacement fluids. Ann Neurol 1987;22:753–761. 

Assessment of plasmapheresis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 1996;47:840–843. 

Dada MA, Kaplan AA. Plasmapheresis treatment in Guillain- Barre syndrome: potential benefit over IVIg in patients with axonal involvement. Ther Apher Dial 2004;8:409–412. 

Hughes RA, Raphael JC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev 2006:CD002063. 

Raphael JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barre syndrome. Cochrane Database Syst Rev 2002:CD001798. 

van der Meche FG, Schmitz PI;Dutch Guillain-Barre Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. N Engl J Med 1992;326:1123–1129. 

Weinstein R. Therapeutic apheresis in neurological disorders. J Clin Apher 2000;15:74–128. 

Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Lancet 1997;349:225–230. 

Lee MC, Campbell R, Born C. Guillain-Barre syndrome after failed pelvic fracture fixation. J Trauma 2009;67:E132–E135. 

Marn Pernat A, Buturovic-Ponikvar J, Svigelj V, Ponikvar R. Guillain-Barre syndrome treated by membrane plasma exchange and/or immunoadsorption. Ther Apher Dial

Fisher TB, Stevens JE. Rehabilitation of a marathon runner with Guillain-Barre syndrome. J Neurol Phys Ther 2008;32: 203–209. 

Furiya Y, Hirano M, Kusunoki S, Ueda M, Sugie K, Nishiwaki T, Ueno S. Complete recovery of an aged patient with Guillain Barre syndrome associated with multiple IgM anti-ganglioside antibodies. Muscle Nerve 2008;38:1630–1633. 

Tripp A. Acute transverse myelitis and Guillain-Barre overlap syndrome following influenza infection. CNS Spectr 2008;13: 744–746. 

Szczeklik W, Jankowski M, Wegrzyn W, Krolikowski W, Zwolinska G, Mitka I, Seczynska B, Nizankowski R. Acute respiratory failure in patients with Guillain-Barre syndrome and myasthenic crisis treated with plasmapheresis in the intensive care unit. Pol Arch Med Wewn 2008;118:239–242. 

Agrawal S, Peake D, Whitehouse WP. Management of children with Guillain-Barre syndrome. Arch Dis Child Educ Pract Ed 2007;92:161–168. 

McGillicuddy DC, Walker O, Shapiro NI, Edlow JA. Guillain- Barre syndrome in the emergency department. Ann Emerg 

Med 2006;47:390–393. 

Falk JA, Cordova FC, Popescu A, Tatarian G, Criner GJ. Treatment of Guillain-Barre syndrome induced by cyclosporine in a lung transplant patient. J Heart Lung Transplant 2006;25: 140–143. 

Arakawa H, Yuhara Y, Todokoro M, Kato M, Mochizuki H, Tokuyama K, Kunimoto F, Morikawa A. Immunoadsorption therapy for a child with Guillain-Barre syndrome subsequent to Mycoplasma infection: a case study. Brain Dev 2005;27: 431–433.